Diagnostic Substances: Palatin Technologies (NYSEMKT:PTN), IDEXX Laboratories (NASDAQ:IDXX), Meridian Bioscience (NASDAQ:VIVO), Quidel Corporation (NASDAQ:QDEL), Atossa Genetics (NASDAQ:ATOS)

Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/311,824 (the ‘824 application). The application includes composition of matter claims on a next generation of melanocortin receptor-specific peptides for sexual dysfunction, obesity, metabolic syndrome and other indications. Palatin Technologies, Inc. (NYSEMKT:PTN) weekly performance is -8.88%. On last trading day company shares ended up $0.975. Analysts mean target price for the company is $4.00. Palatin Technologies, Inc. (NYSEMKT:PTN) distance from 50-day simple moving average is -14.08%.

IDEXX Laboratories (NASDAQ:IDXX) was upgraded by research analysts at Canaccord Genuity from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $148.00 price target on the stock, up from their previous price target of $116.00. Canaccord Genuity’s target price indicates a potential upside of 9.73% from the stock’s previous close.  IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares fell -0.53% in last trading session and ended the day on $134.17. IDXX Gross Margin is 55.10% and its return on assets is 19.30%. IDEXX Laboratories, Inc. (NASDAQ:IDXX) quarterly performance is 10.38%.

Meridian Bioscience (NASDAQ:VIVO) Director Robert J. Ready sold 2,700 shares of Meridian Bioscience stock on the open market in a transaction dated Friday, June 13th. The shares were sold at an average price of $20.03, for a total transaction of $54,081.00. Following the sale, the director now directly owns 13,687 shares of the company’s stock, valued at approximately $274,151. The transaction was disclosed in a document filed with the SEC. Meridian Bioscience, Inc. (NASDAQ:VIVO) shares moved up 0.05% in last trading session and was closed at $20.30, while trading in range of $19.93-$20.46. Meridian Bioscience, Inc. (NASDAQ:VIVO) year to date performance is -22.04%.

Zacks cut shares of Quidel Corp. (NASDAQ:QDEL) from a neutral rating to an underperform rating in a research note issued to investors on Wednesday. The firm currently has $21.00 price target on the stock. Quidel Corporation (NASDAQ:QDEL) ended the last trading day at $22.27. Company weekly volatility is calculated as 2.91% and price to cash ratio as 30.24. Quidel Corporation (NASDAQ:QDEL) showed a negative weekly performance of -7.29%.

Atossa Genetics (Nasdaq: ATOS) announced that it has received international registration for its quality management system.  Atossa Genetics Inc (NASDAQ:ATOS) weekly performance is -5.29%. On last trading day company shares ended up $1.61. Analysts mean target price for the company is $8.75. Atossa Genetics Inc (NASDAQ:ATOS) distance from 50-day simple moving average is 15.94%.